National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Analysis of Health Technology Assessments of Orphan Drugs in Ireland from 2012 to 2017.  Usher C, McCullagh L, Tilson L & Barry M. PharmacoEconomics – Open, (), 1-7.

Incorporating single-arm evidence into a network meta-analysis using aggregate level matching: Assessing the impact Joy Leahy, Howard Thom, Jeroen P. Jansen, Emma Gray, Aisling O’Leary, Arthur White, Cathal Walsh. Statistics in Medicine. 2019;1–19

Supporting prescribing in Irish primary care: protocol for a non-randomised pilot study of a general practice pharmacist (GPP) intervention to optimise prescribing in primary care.  Cardwell K, Clyne B, Moriarty F, Wallace E, Fahey T, Boland F, McCullagh L, Clarke S, Finnigan K, Daly M, Barry M,  Smith SM (on behalf of the General Practice Pharmacist (GPP) Study Group). Pilot and Feasibility Studies 2018 4:122.

Neoadjuvant treatment for malignant and metastatic cutaneous melanoma.  Gorry C, McCullagh L, O’Donnell H, Barrett S, Schmitz S, Barry M, Curtin K, Beausang E, Barry R, Coyne I.  Cochrane Database of Systematic Reviews 2018, Issue 3. Art. No: CD012974. DOI: 10.1002/14651858.CD012974.

Acute herpes zoster and post herpetic neuralgia in primary care: a study of diagnosis, treatment and cost. Crosbie B, Lucey S, Tilson L, Domegan L, Kieran J. Eur J Clin Microbiol Infect Dis. 2017 Dec 7. [Epub ahead of print] PMID: 29218466

Ivacaftor for cystic fibrosis; An evaluation of real world utilisation and expenditure in the Irish Healthcare Setting. Corcoran A, Hickey N, Barry M, Usher C, McCullagh L. Irish Medical journal 2017; 110 (8):

Examining the Feasibility and Utility of Estimating Partial Expected Value of Perfect Information (via a Nonparametric Approach) as Part of the Reimbursement Decision-Making Process in Ireland: Application to Drugs for Cancer. McCullagh L, Schmitz S, Barry M, Walsh C. Pharmacoeconomics. 02/08/2017 DOI: 10.1007/s40273-017-0552-y

The cost of inpatient management of heart failure patients: a microcosting study in the Irish healthcare setting. R B Morgan, L McCullagh, M Barry, C Daly. Irish Journal of Medical Science 11/2016; DOI:10.1007/s11845-016-1514-7

Direct costs of interferon-based and interferon-free DAA regimens for the treatment of chronic hepatitis C infection.  Gray E, O’Leary A, Kieran J, Fogarty E, Dowling T, Norris S.  Journal of Viral Hepatitis, (2016) 2016;23(9):677-86.

High mortality during direct acting antiviral therapy for hepatitis C patients with Child’s C cirrhosis:  Results from an Irish Early Access Programme.  Gray E, O’Leary A, Norris S et al on behalf of the Irish Hepatitis Outcomes Research Network. Journal of Hepatology 2016 Aug;65(2):446-8.

Do Disparities between populations in randomised controlled trails and the real world lead to differences in outcomes? Gray E, O’Leary A, Schmitz S, Norris S. In press.  Journal of Comparative Effectiveness Research, August 2016.

Cost effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients.
Gimeno-Ballester V, Mar J, O’Leary A, Adams R, San Miguel R.  Expert Review Of Gastroenterology & Hepatology 2016

Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis.
Fogarty E, Schmitz S, Tubridy N, Walsh C, Barry M. Mult Scler Relat Disord. 2016 Sep;9:23-30. doi: 10.1016/j.msard.2016.06.001.

The Pharmacoeconomic Evaluation Process in Ireland. 
McCullagh L, Barry M,  PharmacoEconomics 2016; 34(12), 1267-1276 .

Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland. Susanne Schmitz, Laura McCullagh, Roisin Adams, Cathal Walsh. PharmacoEconomics March 2016, 1-13, DOI 10.1007/s40273-016-0406-z.

Cost-effectiveness of natriuretic peptide-based screening and collaborative care: a report from the STOP-HF (St. Vincent’s Screening To Prevent Heart Failure) Study.
Ledwidge M. T, O’Connell E, Gallagher J, Tilson L, James S, Voon V, Bermingham M, Tallon E, Watson C, O’Hanlon R, Barry M and McDonald K.  European Journal of Heart Failure, 17:672-679. doi: 10.1002/ejhf.286

Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?
Godman B, Malmström RE, Diogene E, Gray A, Jayathissa S, Timoney A, Acurcio F, Alkan A, Brzezinska A, Bucsics A, Campbell SM, Czeczot J, de Bruyn W, Eriksson I, Yusof FA, Finlayson AE, Fürst J, Garuoliene K, Guerra Júnior A, Gulbinovič J, Jan S, Joppi R, Kalaba M, Magnisson E, McCullagh L, Miikkulainen K, Ofierska-Sujkowska G, Pedersen HB, Selke G, Sermet C, Spillane S, Supian A, Truter I, Vlahović-Palčevski V, Vien LE, Vural EH, Wale J, Władysiuk M, Zeng W, Gustafsson LL. Expert Rev Clin Pharmacol. 2015 Jan;8(1):77-94. doi: 10.1586/17512433.2015.990380.

Using the Analytic Hierarchy Process to Derive Health State Utilities From Ordinal Preference Data.
Reddy B, Kind P, Adams RC, Walsh C, Barry M. Value in Health 2014;17(7):A513. doi:/10.1016/j/jval.2014.08.1581

Health-related quality of life of patients on opiate replacement therapy.
McLaughlin J, Surah S, Synnott , Adams R, Walsh C, O’Dea S, Noone S, Keenan E, Keating S, Barry M, Bergin C, Mulcahy F, and Lyons F. Heroin Addict Relat Clin Probl 2014 (In press)

Direct and indirect economic consequences of multiple sclerosis in Ireland.
Fogarty, E; Walsh, C; McGuigan, C; Tubridy, N; Barry, M.  Applied Health Economics and Health Policy 2014;12(6):635-645

website link

The cost of the inpatient management of febrile neutropenia in cancer patients – a micro-costing study in the Irish healthcare setting.
C. O’Brien, E. Fogarty, C. Walsh, O. Dempsey, M. Barry, M.J. Kennedy & L. McCullagh. Eur J Cancer Care (Engl), 24: 125–132. doi:10.1111/ecc.12182

Natriuretic Peptide–Based Screening and Collaborative Care for Heart Failure: The STOP-HF Randomized Trial.
Ledwidge M, Gallagher J, Conlon C, Tallon E,  O’Connell E,Dawkins I, Watson C, O’Hanlon R, Bermingham M,  Patle A, MR, Murtagh G, Voon V, Tilson L, Barry M, McDonald L; Maurer B, McDonald K.  JAMA. 2013;310(1):66-74. doi:10.1001/jama.2013.7588.

website link

Health-related quality of life of HIV-infected intravenous drug users.
S Surah, R Adams, L Townsend, I Reynolds, JC Kinahan, S Keating, F Mulcahy, E Keenan, M Barry and F Lyons.  International Journal of STD & AIDS: Volume 24 No 11 November 2013; 867-874.

Personalizing health care: feasibility and future implications.
Godman B, Finlayson, AE, Cheema PK, Zebedin-Brandl E, Gutiérrez-Ibarluzea I, Jones J, Malmström RE, Asola E, Baumgärtel C, Bennie M, Bishop I, Bucsics A, Campbell S, Diogene E, Ferrario A, Fürst J, Garuoliene K, Gomes M, Harris K, Haycox A, Herholz H, Hviding K, Jan S, Kalaba M, Kvalheim C, Laius O, Lööv SA, Malinowska K, Martin A, McCullagh L et al.  BMC Medicine doi:10.1186/1741-7015-11-179. 2013, 11(1):179

website link

Dabigatran – a case history demonstrating the need for comprehensive approaches to optimise the use of new drugs.
Malmstrom R, Godman B, Diogene E, Baumgaertel C, Bennie M, Bishop I, Brzezinska A, Bucsics A, Campbell S, Ferrario A, Finlayson A, Furst J, Garuoliene K, Gomes M, Gutiérrez-Ibarluzea I, Haycox A, Hviding K, Herholz H, Hoffmann M, Jan S, Jones J, Joppi R, Kalaba M, Kvalheim C, Laius O, Langner I, Lonsdale J, Loov SA, Malinowska K, McCullagh L et al.  Front. Pharmacol. | doi: 10.3389/fphar.2013.00039.  May 2013; Volume 4, Article 39. Available at

Website Link

Using resource modelling to inform decision making and service planning:  the case of colorectal cancer screening in Ireland.
Sharpe L, Tilson L, Whyte S, O Ceilleachair A, Walsh C, Usher C, Tappenden P, Chilcott J, Staines A, Barry M, Comber H.  BMC Health Services Research 2013, 13:105 doi:10.1186/1472-6963-13-105

Website Link

Incorporating data from various trial designs into a mixed treatment comparison model.
Schmitz S, Adams R, Walsh C
. Statistics in Medicine.  Article first published online: 25 FEB 2013. DOI:10.1002/sim.5764

Relating Health-related Quality of Life to Disability Progression in Multiple Sclerosis using the Five-level EQ-5D.
Fogarty E, Walsh C, Adams R
, McGuigan C, Barry M, Tubridy N.  Multiple Sclerosis 2013;19(9):1190-1196

website link